Hospital Administration, AMHC, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Bat Yam, Israel
Copyright © 2023 Yeungnam University College of Medicine, Yeungnam University Institute of Medical Science
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
Funding
None.
Author contributions
Conceptualization, Data curation: YG, EG; Formal analysis, Project administration, Supervision: EG; Methodology, Investigation, Software: YG; Writing-original draft: YG; Writing-review & editing: YG, EG.
Study | Year | Study and duration | Participant | Intervention | Control | PSQI outcome |
---|---|---|---|---|---|---|
Jiang et al. [33] | 2010 | Single-blinded, RCT, 4 weeks | People with insomnia | AA (n=63) | AA on sham points (n=62) | As compared to control population, AA improved the quantity and quality of sleep |
Jiao et al. [34] | 2015 | A three-factor (3 needling protocols) and three-level experimental scheme, based on orthogonal method | Patients of insomnia differentiated as internal harassment of phlegm-heat syndrome (n=54) | AA | Body acupuncture and abdominal acupuncture | AA, after body acupuncture, is the second best choice for insomnia |
King et al. [35] | 2015 | A feasibility 3-week study | Veterans with post-traumatic stress disorder and sleep disturbance | Multimodal treatment +9 AA treatments (n=12) | Multimodal treatment without AA (n=8) | Differences between groups were found on sleep quality (p<0.003) and daytime dysfunction (p<0.004) components |
Current study | 2022 | Consecutive case series study, median period of 7.3 weeks | Patients with mental and behavioral disorders due to multiple drug use in therapeutic community | AA according to NADA-Acudetox protocol (n=27) | No | PSQI global score declined by median of 3.0 points (p<0.0001) |
Variable | OR (95% CI) | p-value |
---|---|---|
Age at first use (yr) | 0.76 (0.48–1.20) | 0.240 |
Withdrawal attempts | 0.59 (0.30–1.15) | 0.120 |
Global PSQI score change (point) | 0.73 (0.52–1.01) | 0.055 |
OR, odds ratio; CI, confidence interval; PSQI, Pittsburgh Sleep Quality Index.
For the multivariate logistic regression model, Nagelkerke R2=0.66; sensitivity=92.3%; specificity=81.8%; likelihood-ratio test=16.35; degree of freedom (df)=3; p<0.001; Hosmer–Lemeshow test, χ2=5.84; df=8; p<0.67; area under the receiver operating characteristic curve=0.90 (95% CI, 0.77–1.00), p<0.001.
Study | Year | Study and duration | Participant | Intervention | Control | PSQI outcome |
---|---|---|---|---|---|---|
Jiang et al. [33] | 2010 | Single-blinded, RCT, 4 weeks | People with insomnia | AA (n=63) | AA on sham points (n=62) | As compared to control population, AA improved the quantity and quality of sleep |
Jiao et al. [34] | 2015 | A three-factor (3 needling protocols) and three-level experimental scheme, based on orthogonal method | Patients of insomnia differentiated as internal harassment of phlegm-heat syndrome (n=54) | AA | Body acupuncture and abdominal acupuncture | AA, after body acupuncture, is the second best choice for insomnia |
King et al. [35] | 2015 | A feasibility 3-week study | Veterans with post-traumatic stress disorder and sleep disturbance | Multimodal treatment +9 AA treatments (n=12) | Multimodal treatment without AA (n=8) | Differences between groups were found on sleep quality (p<0.003) and daytime dysfunction (p<0.004) components |
Current study | 2022 | Consecutive case series study, median period of 7.3 weeks | Patients with mental and behavioral disorders due to multiple drug use in therapeutic community | AA according to NADA-Acudetox protocol (n=27) | No | PSQI global score declined by median of 3.0 points (p<0.0001) |
Component | Point, median (IQR) |
Z | p-value | |
---|---|---|---|---|
Pre-AA | Post-AA | |||
C1-Subjective sleep quality | 1.0 (1.0–2.0) | 1.0 (0.0–1.0) | –3.1 | 0.002 |
C2-Sleep latency | 2.0 (1.0–3.0) | 1.0 (0.0–2.0) | –2.5 | 0.011 |
C3-Sleep duration | 1.0 (1.0–2.0) | 1.0 (0.0–1.0) | –1.7 | 0.090 |
C4-Habitual sleep efficiency | 0.0 (0.0–2.0) | 0.0 (0.0–0.25) | –2.3 | 0.023 |
C5-Sleep disturbances | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | –2.7 | 0.007 |
C6-Use of sleeping medication | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | –2.7 | 0.785 |
C7-Daytime dysfunction | 2.0 (1.0–3.0) | 1.0 (0.0–2.0) | –2.4 | 0.015 |
Global score | 9.0 (7.0–13.0) | 6.0 (2.0–7.0) | –3.5 | 0.0001 |
Variable | OR (95% CI) | p-value |
---|---|---|
Age (yr) | 0.92 (0.81–1.03) | 0.15 |
Sex, males vs. females | 1.08 (0.06–19.3) | 0.96 |
LOS in Zoharim pre-AA (day) | 1.01 (0.99–1.02) | 0.17 |
Previous treatments in therapeutic communities | 1.34 (0.40–4.56) | 0.63 |
Previous treatments in Zoharim | 2.20 (0.33–14.73) | 0.42 |
Substance use, drugs with alcohol vs. drugs | 1.67 (0.30–9.16) | 0.56 |
Age at first substance use (yr) | 0.76 (0.58–1.00) | 0.05 |
Withdrawal attempts | 0.61 (0.39–0.96) | 0.03 |
Duration of being free from psychoactive substances | 0.99 (0.96–1.02) | 0.35 |
Global PSQI score pre-AA (point) | 1.04 (0.87–1.25) | 0.67 |
AA treatment sessions | 0.85 (0.68–1.06) | 0.15 |
Length of AA treatments (day) | 0.98 (0.92–1.05) | 0.56 |
Global PSQI score change (point) | 0.76 (0.60–0.96) | 0.02 |
Variable | OR (95% CI) | p-value |
---|---|---|
Age at first use (yr) | 0.76 (0.48–1.20) | 0.240 |
Withdrawal attempts | 0.59 (0.30–1.15) | 0.120 |
Global PSQI score change (point) | 0.73 (0.52–1.01) | 0.055 |
AA, auricular acupuncture; PSQI, Pittsburgh Sleep Quality Index; RCT, randomized controlled trial; NADA, National Acupuncture Detoxification Association.
AA, auricular acupuncture; IQR, interquartile range.
AA, auricular acupuncture; OR, odds ratio; CI, confidence interval; LOS, length of stay; PSQI, Pittsburgh Sleep Quality Index.
OR, odds ratio; CI, confidence interval; PSQI, Pittsburgh Sleep Quality Index. For the multivariate logistic regression model, Nagelkerke R2=0.66; sensitivity=92.3%; specificity=81.8%; likelihood-ratio test=16.35; degree of freedom (df)=3;